The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults
Authors' conclusion
Semaglutide as an add-on treatment to insulin exerted relevant clinical beneficial effects on the glycometabolic control in patients with LADA. These effects are enhanced in those patients with preserved β-cell function.
Study context
- Population
- Patients with latent autoimmune diabetes in adults (LADA) treated with insulin68 continued ≥6 months
- Participants
- 80 patients
- Exposure
- Semaglutide add-on to insulin
- Semaglutiden = 80
- Outcome
- Glycometabolic parameters in semaglutide users
- Follow-up
- 6 months
Main finding
As reported in the abstract
- Significant reduction in HbA1c, BMI and insulin total daily dose
- Serum C-peptide and TIR increased, without changes in TBR
Observational data: associations, not effects.
Further findings
Subgroup by residual β-cell function
- Residual β-cell function: higher BMI and insulin total daily dose reduction
- Preserved β-cell mass: greater TIR improvement vs poor C-peptide production
Suspended insulin bolus administration after starting semaglutide
- Subjects suspending insulin bolus
- 14/68
Treatment continuation · ≥6 months
- Continued semaglutide
- 68
- Oral
- 57/68
- Subcutaneous
- 11/68
- Discontinued treatment
- 12/80
Original publication
The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults. J Clin Endocrinol Metab. Published 23 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →